pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$REGNREGENERON PHARMACEUTICALS, INC.

$REGN955.47+0.45%
Tarrytown, NY, USupdated 1d ago

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
30
marketed
8
phase 3
9
catalysts ytd
10
approvals ytd
3
recalls ytd
0

Pipeline(30)

view full pipeline →
pipeline depth30 products
Preclinical: 1Phase 1: 1Phase 2: 4Phase 3: 9Marketed: 8Unknown: 4pre_registration: 3
1Preclinical1Phase 14Phase 29Phase 38Marketed4Unknown3pre_registration
Marketed
(atoltivimab + maftivimab + odesivimab)
Ebolavirus Infections (Ebola Hemorrhagic Fever)
Marketed
EYLEA HD
wet AMD, diabetic macular edema, retinal vein occlusion
Placenta growth factorVascular endothelial growth factor A, long form
Marketed
Eylea
Diabetic Macular Edema
Marketed
cemiplimab
Melanoma
Programmed cell death protein 1
Marketed
dupilumab
Chronic Urticaria
Interleukin-4 receptor subunit alpha
Marketed
evinacumab
Homozygous Familial Hypercholesterolemia (HoFH)
Marketed
linvoseltamab
Refractory Multiple Myeloma
Marketed
sodium thiosulfate
Hearing Disorders
Phase 3
(atisnolerbart + bremzalerbart + umesolerbart)
Birch Pollen Allergy
Phase 3
cemdisiran + pozelimab
Myasthenia Gravis
Phase 3
fianlimab
Metastatic Melanoma
Lymphocyte activation gene 3 protein
Phase 3
freneslerbart + mevonlerbart
Cat Allergy

📅 Upcoming

Jan 28, 2027
earnings
$REGN955.47+0.45%
in 2mo
REGENERON PHARMACEUTICALS, INC. earnings
REGENERON PHARMACEUTICALS, INC.
→

🕒 Recent(90d)

earnings (2)
Oct 30, 2026
earnings
$REGN955.47+0.45%
16d ago
REGENERON PHARMACEUTICALS, INC. earnings
REGENERON PHARMACEUTICALS, INC.
→
Oct 28, 2026
earnings
$REGN955.47+0.45%
18d ago
REGENERON PHARMACEUTICALS, INC. earnings
REGENERON PHARMACEUTICALS, INC.
→
view all catalysts →

Active trials

  • phase1Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participantsrecruitingn=54
  • —A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Carerecruitingn=350
  • —An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europerecruitingn=500
  • phase4Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthmarecruitingn=250
  • phase3Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanomaactive not recruitingn=1,546
  • phase3A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergycompletedn=54
  • phase2Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myelomarecruitingn=387
  • —An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplantrecruitingn=20
🐶 Hiring Signal
next earnings Jan 28, 2027
633 open roles at REGENERON PHARMACEUTICALS, INC. →

Where REGENERON PHARMACEUTICALS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 44Immunology & Inflammation 28Hematology 20CNS / Neuroscience 19Rare Disease 11Ophthalmology 9
departmentR&D / Discovery 82Quality 50Medical Affairs 48IT & Engineering 46Manufacturing / CMC 40Regulatory 28

News

  • Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
    Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
    biospace · 2d ago
  • 10 companies hiring in New Jersey
    Looking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.
    biospace · 3d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 5d ago
  • The top 12 companies hiring in biopharma now
    Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.
    biospace · 10d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 16d ago
  • 8 companies hiring in New York
    Looking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month.
    biospace · 17d ago
  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
    Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…
    biospace · 1mo ago
  • STAT+: Sanofi, Regeneron expand partnership after Dupixent success
    Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
    stat · 1mo ago
  • FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
    The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…
    biospace · 1mo ago
view all news mentions →
identifiers
ticker
$REGN
SEC CIK
0000872589
country
US
source
sec_tickers
top tags
Immunology6Oncology6Pulmonology2Asthma1DLBCL1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 38m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?